Mywy (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

Drospirenone/Ethinylestradiol, the active ingredients in Mywy, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy by suppressing ovulation and altering cervical mucus in women of reproductive age.

GNH USA supplies Mywy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mywy, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy.

- Prevention of pregnancy: provides reliable contraception for women of childbearing potential. - Regulation of menstrual cycles: helps achieve more predictable bleeding patterns. - Treatment of moderate acne: reduces androgen‑driven skin lesions in eligible patients.

Mywy may cause a range of adverse reactions. Most are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional throbbing pain. - Spotting or breakthrough bleeding: irregular light bleeding. - Weight gain: modest increase in body weight. - Mood changes: irritability or mood swings.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: new‑onset or worsening high blood pressure. - Liver disorders: cholestatic jaundice or hepatic dysfunction. - Gallbladder disease: gallstones or cholecystitis. - Severe allergic reaction: anaphylaxis or angioedema.

Before prescribing Mywy, clinicians should evaluate individual risk factors and counsel patients on safe use.

- Assess cardiovascular risk: review history of thrombosis, smoking, and hypertension. - Screen for liver disease: avoid use in active hepatic impairment. - Evaluate migraine history: contraindicated in migraine with aura. - Counsel on smoking: advise cessation, especially in women >35 years. - Review medication list: consider potential drug interactions. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Mywy can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Other estrogen‑containing products (e.g., hormone therapy): increase overall estrogen exposure and risk of thromboembolism.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole, itraconazole): may increase plasma levels of ethinylestradiol. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): can modestly raise estrogen concentrations. - Antidepressants (e.g., SSRIs): may increase risk of mood‑related side effects.